AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31737860 — intervention group
Group type: EXPERIMENTAL
Intervention: Red beetroot juice (RBJ)
Number of subjects: 15
Study 31737860 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 15
Study 31737860 — intervention group
Group type: COMPARATOR
Intervention: PBO + NIT
Number of subjects: 15
Study 31737860 — intervention group
Group type: COMPARATOR
Intervention: NF-RBJ
Number of subjects: 15
Study 31738177 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported food frequency questionnaire
Number of subjects: 802
Study 31738177 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine spot sample analysis
Number of subjects: 802
Study 31738180 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-driven monitoring solution with automatic alerts
Number of subjects: 25
Study 31738180 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-driven monitoring solution
Number of subjects: 25
Study 31738181 — intervention group
Group type: EXPERIMENTAL
Intervention: Early AKI (defined by an increase in serum creatinine >0.3 mg/dl or urine output <1 ml/kg per hour on postnatal days 2-7)
Number of subjects: 2110
Study 31738181 — intervention group
Group type: EXPERIMENTAL
Intervention: Early AKI
Number of subjects: 2110
Study 31738425 — intervention group
Group type: EXPERIMENTAL
Intervention: larotrectinib (20 mg/kg twice daily)
Number of subjects: 1
Study 31738892 — intervention group
Group type: EXPERIMENTAL
Intervention: CO-OP KT intervention
Number of subjects: 0
Study 31738892 — intervention group
Group type: COMPARATOR
Intervention: Historical control (not exposed to CO-OP KT)
Number of subjects: 0
Study 31739088 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admission (unplanned patients)
Number of subjects: 1300
Study 31739088 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU admission (planned patients)
Number of subjects: 1300
Study 31739232 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcoleptic patients
Number of subjects: 69
Study 31739771 — intervention group
Group type: EXPERIMENTAL
Intervention: SPG stimulation with real-time optical tracking guidance and comfortable tolerance level selection based on facial physiological markers.
Number of subjects: 50
Study 31739771 — intervention group
Group type: EXPERIMENTAL
Intervention: SPG stimulation
Number of subjects: 50
Study 31739854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual minority females
Number of subjects: 1946
Study 31739854 — intervention group
Group type: COMPARATOR
Intervention: Heterosexual females
Number of subjects: 1946
Study 31739856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 59
Study 31739856 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 59
Study 31739856 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence with MAD
Number of subjects: 59
Study 31739856 — intervention group
Group type: COMPARATOR
Intervention: Self-reported adherence with CPAP
Number of subjects: 59
Study 31740109 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent age at onset (AAO)
Number of subjects: 3184
Study 31740109 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adult age at onset (AAO)
Number of subjects: 3184
Study 31740109 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle age age at onset (AAO)
Number of subjects: 3184
Study 31740109 — intervention group
Group type: EXPERIMENTAL
Intervention: Child age at onset (AAO)
Number of subjects: 3184
Study 31740109 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 3184
Study 31740479 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-affirming hormone therapy in transgender men (TM)
Number of subjects: 90
Study 31740479 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-affirming hormone therapy in transgender women (TW)
Number of subjects: 90
Study 31740981 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based follow-up using EORTC-QLQ-C30 questionnaires
Number of subjects: 29
Study 31740996 — intervention group
Group type: EXPERIMENTAL
Intervention: Exeter stem
Number of subjects: 2528
Study 31740996 — intervention group
Group type: COMPARATOR
Intervention: SP2 stem
Number of subjects: 2528
Study 31741153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (ICA)
Number of subjects: 1225
Study 31741153 — intervention group
Group type: COMPARATOR
Intervention: Extra-corporeal anastomosis (ECA)
Number of subjects: 1225
Study 31741744 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-adapted Diabetes Prevention Program (DPP)
Number of subjects: 40
Study 31741746 — intervention group
Group type: EXPERIMENTAL
Intervention: Early in-bed cycling intervention with mechanically ventilated patients in the ICU
Number of subjects: 53
Study 31741746 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation Practice and Research
Number of subjects: 53
Study 31741746 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation barriers
Number of subjects: 53
Study 31741745 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care and exercise (8 supervised exercise sessions combined with home-based exercise over a 10-week period)
Number of subjects: 30
Study 31741745 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30
Study 31741774 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived T cells
Number of subjects: 39
Study 31741774 — intervention group
Group type: COMPARATOR
Intervention: Peripheral blood-derived T cells
Number of subjects: 39
Study 31741786 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates Group (PG)
Number of subjects: 60
Study 31741786 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular Group (MG)
Number of subjects: 60
Study 31741786 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 60
Study 31742250 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-2 visual field tests
Number of subjects: 180
Study 31742250 — intervention group
Group type: COMPARATOR
Intervention: C24-2 visual field tests
Number of subjects: 180
Study 31742564 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower vitamin D group (<25 ng/ml), n=22
Number of subjects: 43
Study 31742564 — intervention group
Group type: COMPARATOR
Intervention: Higher vitamin D group (≥25 ng/ml), n=21
Number of subjects: 43
Study 31742568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of neck anatomy
Number of subjects: 194
Study 31742568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound distances measured (including DSHB)
Number of subjects: 194
Study 31742568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment
Number of subjects: 194
Study 31743993 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Chondrocytes (NC)
Number of subjects: 13
Study 31743993 — intervention group
Group type: COMPARATOR
Intervention: Debrided Knee Chondrocytes (dKC)
Number of subjects: 13
Study 31743993 — intervention group
Group type: COMPARATOR
Intervention: Debrided Knee Chondrocytes (dKC) with TGFβ1 supplementation
Number of subjects: 13
Study 31744224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreservation of ovarian tissue (OT)
Number of subjects: 0
Study 31744224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreservation of testicular tissue (TT)
Number of subjects: 0
Study 31744489 — intervention group
Group type: EXPERIMENTAL
Intervention: COBPeer tool
Number of subjects: 119
Study 31744489 — intervention group
Group type: COMPARATOR
Intervention: Usual peer-review process
Number of subjects: 119
Study 31744781 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 565253
Study 31744781 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 565253
Study 31744781 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 565253
Study 31744781 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion monotherapy
Number of subjects: 565253
Study 31744781 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRI) mono-class therapy
Number of subjects: 565253
Study 31744781 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion and SSRI combinations
Number of subjects: 565253
Study 31744781 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic-containing regimens
Number of subjects: 565253
Study 31744781 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-class polypharmacy
Number of subjects: 565253
Study 31744781 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 565253
Study 31744867 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing assessment (9 criteria evaluated by a physiotherapist)
Number of subjects: 159
Study 31744867 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of one or both gag reflexes
Number of subjects: 159
Study 31744867 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 159
Study 31744891 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic and bariatric surgery (MBS)
Number of subjects: 242
Study 31744895 — intervention group
Group type: EXPERIMENTAL
Intervention: ERK Inhibitor LY3214996
Number of subjects: 0
Study 31745384 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum biomarkers for predicting outcomes in children with DCM and HCM
Number of subjects: 288
Study 31745384 — intervention group
Group type: EXPERIMENTAL
Intervention: New onset DCM cohort
Number of subjects: 288
Study 31745384 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic DCM or HCM cohort
Number of subjects: 288
Study 31745699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (10, 45, and 90 days duration)
Number of subjects: 3
Study 31745699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3
Study 31745703 — intervention group
Group type: EXPERIMENTAL
Intervention: buparlisib and olaparib
Number of subjects: 18
Study 31745902 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstage renal impairment (RI)
Number of subjects: 705
Study 31745902 — intervention group
Group type: COMPARATOR
Intervention: No interstage renal impairment (RI)
Number of subjects: 705
Study 31746632 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0
Study 31746688 — intervention group
Group type: EXPERIMENTAL
Intervention: CT angiography with CT perfusion imaging
Number of subjects: 0
Study 31746688 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive coronary angiography (ICA) and SPECT
Number of subjects: 0
Study 31746765 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamification interventions with social incentives
Number of subjects: 361
Study 31746765 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 361
Study 31747004 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-anticoagulated patients with non-paroxysmal AF patterns
Number of subjects: 29181
Study 31747004 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulated patients with non-paroxysmal AF patterns
Number of subjects: 29181
Study 31747004 — intervention group
Group type: COMPARATOR
Intervention: Non-anticoagulated patients with paroxysmal AF patterns
Number of subjects: 29181
Study 31747004 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulated patients with all AF patterns
Number of subjects: 29181
Study 31747668 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge eaters
Number of subjects: 300
Study 31747668 — intervention group
Group type: EXPERIMENTAL
Intervention: Snack eaters
Number of subjects: 300
Study 31747668 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet eaters
Number of subjects: 300
Study 31747668 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating habits
Number of subjects: 300
Study 31747668 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall eating patterns
Number of subjects: 300
Study 31747668 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (ΔBMI)
Number of subjects: 300
Study 31747879 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms (PREVENT) quality improvement intervention
Number of subjects: 0
Study 31747879 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation activities of the PREVENT intervention
Number of subjects: 0
Study 31747885 — intervention group
Group type: EXPERIMENTAL
Intervention: D2-plus lymphadenectomy for No. 8p lymph nodes
Number of subjects: 128
Study 31747885 — intervention group
Group type: EXPERIMENTAL
Intervention: D2-plus lymphadenectomy for No. 12b lymph nodes
Number of subjects: 128
Study 31747885 — intervention group
Group type: EXPERIMENTAL
Intervention: D2-plus lymphadenectomy for No. 12p lymph nodes
Number of subjects: 128
Study 31747885 — intervention group
Group type: EXPERIMENTAL
Intervention: D2-plus lymphadenectomy for No. 13 lymph nodes
Number of subjects: 128
Study 31747885 — intervention group
Group type: EXPERIMENTAL
Intervention: D2-plus lymphadenectomy for No. 14v lymph nodes
Number of subjects: 128
Study 31748196 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-defibrillator devices (74.3% of subjects), mainly quadripolar LV leads (75%) deployed laterally (78%)
Number of subjects: 1524
Study 31748196 — intervention group
Group type: COMPARATOR
Intervention: Site-defined nonresponders
Number of subjects: 1524
Study 31748196 — intervention group
Group type: COMPARATOR
Intervention: Site-defined responders
Number of subjects: 1524
Study 31748220 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31748235 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive troponin result (higher than the upper limit of normal)
Number of subjects: 257948
Study 31748235 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive troponin result
Number of subjects: 257948
Study 31748235 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin level in patients without acute coronary syndrome (ACS)
Number of subjects: 257948
Study 31748235 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin level in patients with ACS
Number of subjects: 257948
Study 31748235 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin level in patients managed invasively with ACS
Number of subjects: 257948
Study 31748235 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin level in patients managed non-invasively with ACS
Number of subjects: 257948
Study 31748245 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of radical hysterectomy or other cervical procedure followed by definitive chemoradiation
Number of subjects: 718
Study 31748245 — intervention group
Group type: COMPARATOR
Intervention: Abandonment of planned cervical procedure followed by definitive chemoradiation
Number of subjects: 718
Study 31748285 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased arterial stiffness in patients with HFpEF (Group D)
Number of subjects: 5
Study 31748285 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy volunteers without major comorbidities (Group A)
Number of subjects: 5
Study 31748285 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hypertension without diabetes (Group B)
Number of subjects: 5
Study 31748285 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hypertension and diabetes (Group C)
Number of subjects: 5
Study 31748285 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with heart failure and reduced ejection fraction (Group E)
Number of subjects: 5
Study 31748293 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth patterns measured by body mass index trajectories
Number of subjects: 0
Study 31748293 — intervention group
Group type: EXPERIMENTAL
Intervention: Other health trajectories including health behaviours, nutrition, cardiometabolic risk and development
Number of subjects: 0
Study 31749377 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle behavioral intervention
Number of subjects: 0
Study 31749387 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical triggering events
Number of subjects: 0
Study 31749387 — intervention group
Group type: COMPARATOR
Intervention: Non-medical triggering events
Number of subjects: 0
Study 31749387 — intervention group
Group type: COMPARATOR
Intervention: No triggering events
Number of subjects: 0
Study 31749608 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa enzyme replacement therapy (ERT)
Number of subjects: 152
Study 31749731 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based behavioral intervention
Number of subjects: 20
Study 31749731 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 20
Study 31749854 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusing alpha emitters radiation therapy (DaRT) applied to one lesion.
Number of subjects: 1
Study 31749981 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 31
Study 31749981 — intervention group
Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Exercise (MICE)
Number of subjects: 31
Study 31750307 — intervention group
Group type: EXPERIMENTAL
Intervention: Three different exercise strategies, details on dosage and duration not available
Number of subjects: 0
Study 31750396 — intervention group
Group type: EXPERIMENTAL
Intervention: ranibizumab 0.3 mg
Number of subjects: 759
Study 31750396 — intervention group
Group type: EXPERIMENTAL
Intervention: ranibizumab 0.5 mg
Number of subjects: 759
Study 31750396 — intervention group
Group type: COMPARATOR
Intervention: sham treatment (crossover to ranibizumab 0.5 mg at month 24)
Number of subjects: 759
Study 31750837 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored self-help mobile app (Recovery Record)
Number of subjects: 959
Study 31750837 — intervention group
Group type: COMPARATOR
Intervention: Standard self-monitoring app (cognitive behavioral therapy-based)
Number of subjects: 959
Study 31750899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1753
Study 31750899 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1753
Study 31750988 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPROD bpMRI findings
Number of subjects: 499
Study 31750988 — intervention group
Group type: EXPERIMENTAL
Intervention: Model incorporating clinical variables
Number of subjects: 499
Study 31750988 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative DWI-based score
Number of subjects: 499
Study 31751853 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab 100 mg subcutaneously (SC)
Number of subjects: 0
Study 31751853 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab 100 mg SC
Number of subjects: 0
Study 31751853 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 31751906 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic scoring of cardiorespiratory polygraphy
Number of subjects: 204
Study 31751906 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual scoring of cardiorespiratory polygraphy
Number of subjects: 204
Study 31751906 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen desaturation 4% index (ODI4)
Number of subjects: 204
Study 31751906 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest saturation
Number of subjects: 204
Study 31751906 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent of time spent <90% saturation
Number of subjects: 204
Study 31751906 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory event index (REI)
Number of subjects: 204
Study 31751906 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive apnea index
Number of subjects: 204
Study 31752504 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended follow-up intervals for INR monitoring, specific dosage and duration not available
Number of subjects: 0
Study 31752504 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up intervals for INR monitoring, specific dosage and duration not available
Number of subjects: 0
Study 31752709 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention of palliative care principles
Number of subjects: 40
Study 31752709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing home care
Number of subjects: 40
Study 31752709 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care
Number of subjects: 40
Study 31752709 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased knowledge and education regarding palliative care
Number of subjects: 40
Study 31752726 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography (OCTA)
Number of subjects: 0
Study 31752726 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic factors (metabolic control, HbA1c, lipid profile, cholesterol, etc.)
Number of subjects: 0
Study 31752726 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA-derived parameters
Number of subjects: 0
Study 31752752 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metformin at doses up to 3000 mg per day for 3 months
Number of subjects: 49
Study 31752882 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin carotenoid status (SCS) assessed using resonance Raman spectroscopy (RRS)
Number of subjects: 52
Study 31752882 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin carotenoid status (SCS) assessed using pressure-mediated reflection spectroscopy (RS)
Number of subjects: 52
Study 31752882 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported vegetable and fruit (VF) intake
Number of subjects: 52
Study 31752911 — intervention group
Group type: EXPERIMENTAL
Intervention: ReWalk exoskeleton training for 12 weeks
Number of subjects: 12
Study 31752951 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-mobility cup and cementless triple-taper femoral stem combination
Number of subjects: 244
Study 31752976 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antimicrobial therapy
Number of subjects: 282
Study 31752976 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay to appropriate antimicrobial treatment
Number of subjects: 282
Study 31752976 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antimicrobial therapy
Number of subjects: 282
Study 31752976 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged antimicrobial therapy (>7 days)
Number of subjects: 282
Study 31752976 — intervention group
Group type: COMPARATOR
Intervention: Mono versus polymicrobial S. maltophilia HAP
Number of subjects: 282